Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Chardan Capital Markets Starts Livongo Health Inc. (LVGO) at Neutral
-
Precision BioSciences Reports Second Quarter 2019 Financial Results and Highlights Ongoing Operational Progress
-
Precision BioSciences Reports Second Quarter 2019 Financial Results and Highlights Ongoing Operational Progress
-
MeiraGTx Holdings plc (MGTX) Prices 3.2M Share Common Offering at $23.50/Sh
-
MeiraGTx Announces Pricing of Public Offering of Ordinary Shares
-
MeiraGTx Announces Pricing of Public Offering of Ordinary Shares
-
MeiraGTx Holdings plc (MGTX) Announces Proposed $75M Public Offering of Ordinary Shares
-
MeiraGTx Announces Proposed Public Offering of Ordinary Shares
-
MeiraGTx Announces Proposed Public Offering of Ordinary Shares
-
Orisun Acquisition Corp. (ORSN) Prices 4M Unit IPO at $10/Unit
-
Orisun Acquisition Corp. Announces Pricing of $40 Million Initial Public Offering
-
Exicure Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
-
Exicure Inc. (XCUR) Prices 27.5M Share Common Offering at $2/Sh; Announces Uplisting to Nasdaq Market
-
Exicure Announces Uplisting to Nasdaq Capital Market and Pricing of $55 Million Public Offering of Common Stock
-
PlacementTracker Publishes Q2 2019 PIPE and Private Placement Markets League Tables
-
Chardan Capital Markets Starts Phreesia Inc. (PHR) at Buy
-
Chardan Capital Markets Starts Replimune Group (REPL) at Buy
-
Chardan Capital Markets Downgrades VistaGen Therapeutics (VTGN) to Neutral
-
Form DEFA14A Chardan Healthcare Acqui
-
Form 8-K Chardan Healthcare Acqui For: Jul 17
-
Chardan Healthcare Acquisition Corp. Announces Merger Agreement with BiomX Ltd.
-
Form PREM14A Chardan Healthcare Acqui For: Jul 16
-
Form 8-K Chardan Healthcare Acqui For: Jul 16
-
Form DEFA14A Chardan Healthcare Acqui
-
Chardan Healthcare Acquisition Corp. (CHAC) Reports Merger Agreement with BiomX Ltd.
-
Chardan Healthcare Acquisition Corp. Announces Merger Agreement with BiomX Ltd.
-
Chardan Healthcare Acquisition Corp. Announces Merger Agreement with BiomX Ltd.
-
Synlogic Inc. (SYBX) PT Raised to Street High $25 at Chardan Capital Markets
-
Pre-Open Movers 07/11: (IMUX) (OMER) (DVAX) (CI) (CVS) (WW) (SNSS) (BBBY) (FAST) (more...)
-
Chardan Capital Markets Starts Immunic Inc. (IMUX) at Buy
-
8i Enterprises Acquisition Corp. Announces Execution of Share Exchange Agreement with Diginex Limited
-
Teladoc (TDOC) PT Lowered to $90 at Chardan Capital Markets
-
Vuzix Corp. (VUZI) Offering Should Provide Capital Through Next 18 Months - Chardan
-
Chardan Capital Markets Upgrades HMS Holdings (HMSY) to Buy
-
Chanticleer Holdings Extends Rights Offering to 4:00 PM Eastern Time on Friday, June 28, 2019
-
Chanticleer Holdings Extends Rights Offering to 4:00 PM Eastern Time on Friday, June 28, 2019
-
Krystal Biotech (KRYS) Prices 2.5M Share Common Offering at $40/Sh
-
Krystal Biotech Announces Pricing of $100.0 Million Public Offering of Common Stock
-
Krystal Biotech (KRYS) PT Raised to $75 at Chardan Capital Markets
-
La Jolla Pharma (LJPC) PT Lowered to $20 at Chardan Capital Markets
-
Locust Walk Further Expands Financing Team with Appointments of Neil Higgins and Turner Grant
-
Smith Micro Software (SMSI) Could See Boost From New Sprint Service - Chardan
-
Voyager Therapeutics (VYGR) PT Doubled to $30 at Chardan Capital Markets
-
InVitae (NVTA) PT Rises To $30 At Chardan On 47% Revenue Growth
-
Chardan Capital Markets Starts Provention Bio Inc. (PRVB) at Buy
-
Regenxbio Inc. (RGNX) PT Raised to $145 at Chardan Capital Markets
-
Tocagen Inc. (TOCA) PT Lowered to $10 at Chardan Capital Markets
-
Vuzix Corp. (VUZI) Faces New Challenges With Google Glass 2, Reit Buy At Chardan
-
Iovanace Biotherapeutics (IOVA) PT Raised to $30 at Chardan Capital Markets
-
NanoViricides Files Quarterly Report for Period Ending March 31, 2019 - HerpeCide™ Drug Candidate Pre-IND Application Submitted, Progressing Towards Clinical Trials

